Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
Inv. presentation
CC transcript
Asset disposition
|
|
Cyclacel Pharmaceuticals, Inc. (CYCC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
8-K
| Quarterly results |
| 03/09/2023 |
8-K
| Other Events Interactive Data |
| 03/06/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 01/06/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 12/30/2022 |
8-K
| Quarterly results |
| 12/09/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
8-K
| Quarterly results |
| 10/31/2022 |
8-K
| Quarterly results |
| 09/13/2022 |
8-K
| Other Events Interactive Data |
| 08/10/2022 |
8-K
| Quarterly results |
| 06/16/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 03/28/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/16/2022 |
8-K
| Other Events Interactive Data |
| 12/15/2021 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Quarterly results |
| 09/09/2021 |
8-K
| Quarterly results |
| 08/11/2021 |
8-K
| Quarterly results |
| 06/17/2021 |
8-K
| Quarterly results |
| 05/12/2021 |
8-K
| Quarterly results |
| 03/23/2021 |
8-K
| Quarterly results |
| 03/15/2021 |
8-K
| Quarterly results |
| 02/25/2021 |
8-K
| Quarterly results |
| 02/23/2021 |
8-K
| Quarterly results |
| 01/15/2021 |
8-K
| Quarterly results |
| 12/22/2020 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...|
Docs:
|
"Certificate of Designation of Preferences, Rights and Limitations of the Series B Convertible Preferred Stock",
"Form of Warrant",
"Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.",
"Form of Securities Purchase Agreement",
"Cyclacel Pharmaceuticals ANNOUNCES At-the-market $7 MILLION strategic INVESTMENT BY FUNDAMENTAL INVESTOR ACORN BIOVENTURES" |
|
| 12/21/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/12/2020 |
8-K
| Quarterly results, Appointed a new director |
| 10/29/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Cyclacel Pharmaceuticals ANNOUNCES APPOINTMENT OF MARK KIRSCHBAUM, m.d., AS CHIEF MEDICAL OFFICER Berkeley Heights, NJ, October 23, 2020 Cyclacel Pharmaceuticals, Inc. , a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced the appointment of Mark Kirschbaum, M.D. as Senior Vice President & Chief Medical Officer . Dr. Kirschbaum is a highly experienced hematologist/oncologist with over 30 years of experience in molecular medicine, new drug development, clinical trial design and patient care. He has management experience in both academic research and clinical and pharmaceutical settings. As CMO, he will be responsible for advancing Cyclacel’ s pipeline and will lead clinical strategy, patient safety, and medical affairs. “We are delighted to wel..." |
|
| 09/15/2020 |
8-K
| Other Events |
| 09/09/2020 |
8-K
| Quarterly results |
|
|
|